Yang Ming StemMax, Inc.’s world-first patented R&D technology can effectively reverse and repair pulmonary fibrosis, which is currently incurable with existing drugs. The irreversible and progressive deterioration of pulmonary fibrosis causes respiratory failure leading to death. The US FDA-approved anti-pulmonary fibrosis drugs, Esbriet and Ofev, can only slow down the rate of fibrosis and cannot cure the disease. Professor Yu-Show Fu, the founder of Yang Ming StemMax, Inc., starting from the Department of Anatomy of the College of Medicine at National Yang Ming Chiao Tung University, led the R&D team to successfully use allogeneic (non-self) umbilical cord mesenchymal stem cells to reverse and repair pulmonary fibrosis. The team has taken the lead in obtaining multiple patents, awakening the autologous regeneration mechanism through emerging cell therapies to achieve therapeutic repair effects. Experiments have proven that the safety, efficacy, and cost of human umbilical cord mesenchymal stem cells are superior to both of the current anti-fibrotic drugs as well as adipose-derived mesenchymal stem cells. The cell preparations of Yang Ming StemMax, Inc. have high safety, and the cells still maintain stable stem cell characteristics even after twenty passages. Patients do not need to store their own umbilical cords; when needed, they can immediately obtain the treatment that reverses and repairs pulmonary fibrosis from the cell bank.